CTOs on the Move

advantishc

www.advantishc.com

 
advantishc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NetMed Medical Transcription Services

NetMed Medical Transcription Services is a Cadillac, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Health and Rejuvenation Center

The Health and Rejuvenation Center is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inner Dimension TV

Inner Dimension TV is a monthly subscription platform full of high-quality cinematic yoga and meditation classes. Start your 10-day free trial today.

Transcarent

Transcarent is a new consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, Health Guides and data science, Transcarent empowers consumers with unbiased information, trusted guidance and access to high-value care.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.